Eloralintide
Metabolic Health · Amylin receptor agonist
Tier B-
Bottom line
Read Off Label grades Eloralintide as B- (5.9/10) based on moderate evidence, high benefit magnitude, and a med-risk safety profile.
Eli Lilly selective amylin agonist.
Studied, labeled, or reported-use context: SC once weekly; Phase 2 dose-ranging — Investigational; not individualized guidance.
What the evidence says
Eli Lilly selective amylin agonist. Phase 2 (n=263, 48 weeks; published Lancet Nov 2025): mean weight loss 9.5-20.1% across doses vs 0.4% placebo, with cardiometabolic improvements and GI adverse events near placebo at lower doses. First long-acting amylin monotherapy beyond pramlintide. Phase 3 enrolling. Industry-sponsored.
Mechanism
Long-acting selective amylin receptor agonist (monotherapy and tirzepatide stack partner); amylin signaling drives satiety and slows gastric emptying independent of GLP-1.
Studied, labeled, or reported dose & route
SC once weekly; Phase 2 dose-ranging
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Eloralintide's effects?
- Read Off Label rates the evidence for Eloralintide as Moderate and the benefit magnitude as high, producing an overall grade of B- (5.9/10). Eli Lilly selective amylin agonist.
- What safety findings are reported for Eloralintide?
- Eloralintide has a med risk profile in the database. Med (mild-moderate GI; near placebo at lower doses) Legal status: Investigational (Phase 3).
- What doses or routes are reported for Eloralintide?
- SC once weekly; Phase 2 dose-ranging This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Eloralintide work?
- Long-acting selective amylin receptor agonist (monotherapy and tirzepatide stack partner); amylin signaling drives satiety and slows gastric emptying independent of GLP-1.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.